Contribution of plasminogen activators and their inhibitors to the survival prognosis of patients with Dukes' stage B and C colorectal cancer
about
Tumor marker utility and prognostic relevance of cathepsin B, cathepsin L, urokinase-type plasminogen activator, plasminogen activator inhibitor type-1, CEA and CA 19-9 in colorectal cancer.Prognostic biomarkers in resected colorectal cancer: implications for adjuvant chemotherapy.Regulation of the human plasminogen activator inhibitor type 2 gene: cooperation of an upstream silencer and transactivator.MMP-2 and MMP-9 in normal mucosa are independently associated with outcome of colorectal cancer patients.Targeting the urokinase plasminogen activator receptor with a monoclonal antibody impairs the growth of human colorectal cancer in the liver.Tumour markers of prognosis in colorectal cancer.Clinical utility of level-of-evidence-1 disease forecast cancer biomarkers uPA and its inhibitor PAI-1.Impact of proteolytic enzymes in colorectal cancer development and progression.Urokinase-type plasminogen activator and its receptor in colorectal cancer: independent prognostic factors of metastasis and cancer-specific survival and potential therapeutic targets.ARNTL2 and SERPINE1: potential biomarkers for tumor aggressiveness in colorectal cancer.Insulinlike growth factor-I-mediated migration and invasion of human colon carcinoma cells requires activation of c-Met and urokinase plasminogen activator receptor.Proteases as prognostic markers in cancer.Plasminogen activator system, vascular endothelial growth factor, and colorectal cancer progression.Peritoneal response to pneumoperitoneum and laparoscopic surgery.Proteases in cutaneous melanoma
P2860
Q33350682-FFB601EF-C5F4-443A-9416-7313FEA27B44Q34733963-2AE34C1F-4862-4F08-8F7F-64CBDD3D27CFQ35879991-9C6CE246-A995-4D48-8C75-E0FDFACC582BQ35927127-788E02F7-4DD4-466F-BF40-FD6F5F751052Q36168520-5290CCC1-1F15-408C-9948-50A5F84DD621Q36617345-7D8CEB2F-577B-41EF-9BA0-324A1D2BE5F7Q37809871-498EE8B6-495B-49BF-AC72-FE112C0F63AAQ38259533-02133DE1-FB2E-4453-83BE-6AB6FA93BF1AQ38308022-66A4CC1A-778C-4F8F-AEB8-C87ADAD5BF1EQ39422383-EDB5ADDA-3F3F-4CC6-998E-53EE98FDC775Q40431244-94172D3C-0514-402E-9254-58EF6B2F5C36Q42756100-A78B16A6-7E08-4657-8870-B8C61E56748EQ42937214-12C3E54F-4AB8-4D80-B537-C461112FF4F5Q50174498-15A4BDDB-BCEE-4F4A-B0B4-A77016A5F6EFQ58136328-964B2047-AC52-4E54-922A-4C4EF4799AD3
P2860
Contribution of plasminogen activators and their inhibitors to the survival prognosis of patients with Dukes' stage B and C colorectal cancer
description
1997 nî lūn-bûn
@nan
1997年の論文
@ja
1997年学术文章
@wuu
1997年学术文章
@zh-cn
1997年学术文章
@zh-hans
1997年学术文章
@zh-my
1997年学术文章
@zh-sg
1997年學術文章
@yue
1997年學術文章
@zh
1997年學術文章
@zh-hant
name
Contribution of plasminogen ac ...... tage B and C colorectal cancer
@ast
Contribution of plasminogen ac ...... tage B and C colorectal cancer
@en
type
label
Contribution of plasminogen ac ...... tage B and C colorectal cancer
@ast
Contribution of plasminogen ac ...... tage B and C colorectal cancer
@en
prefLabel
Contribution of plasminogen ac ...... tage B and C colorectal cancer
@ast
Contribution of plasminogen ac ...... tage B and C colorectal cancer
@en
P2093
P2860
P356
P1476
Contribution of plasminogen ac ...... tage B and C colorectal cancer
@en
P2093
Griffioen G
Heerding MM
Verheijen JH
Verspaget HW
Welvaart K
van Krieken JH
van de Velde CJ
P2860
P2888
P304
P356
10.1038/BJC.1997.306
P407
P577
1997-01-01T00:00:00Z